[SPSETIA] YoY Cumulative Quarter Result on 31-Dec-2018 [#4]

Stock
[SPSETIA] SP SETIA BHD
Announcement Date
27-Feb-2019
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2018
Quarter
31-Dec-2018 [#4]
Profit Trend
QoQ- 17.83%
YoY- -28.07%
Quarter Report
Latest QR
Upcoming QR
SPSETIA's Result
SPSETIA's Financial Summary
View:
Show?
Cumulative Result
31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/10/13 31/10/12 CAGR
Revenue 3,762,748 3,228,117 3,928,874 3,593,589 4,520,112 3,261,159 2,526,595 4.43%
PBT 542,464 -156,650 598,230 990,548 1,271,417 658,415 567,505 -0.49%
Tax -195,119 -87,872 -176,199 -192,253 -202,385 -173,983 -179,877 0.89%
NP 347,345 -244,522 422,031 798,295 1,069,032 484,432 387,628 -1.18%
-
NP to SH 284,365 -321,026 343,720 670,959 932,857 418,348 393,816 -3.48%
-
Tax Rate 35.97% - 29.45% 19.41% 15.92% 26.42% 31.70% -
Total Cost 3,415,403 3,472,639 3,506,843 2,795,294 3,451,080 2,776,727 2,138,967 5.23%
-
Net Worth 12,070,054 11,805,090 12,208,294 11,920,759 9,747,586 5,197,006 3,859,435 13.23%
Dividend
31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/10/13 31/10/12 CAGR
Div 26,505 - 40,424 336,377 530,131 256,354 268,816 -22.31%
Div Payout % 9.32% - 11.76% 50.13% 56.83% 61.28% 68.26% -
Equity
31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/10/13 31/10/12 CAGR
Net Worth 12,070,054 11,805,090 12,208,294 11,920,759 9,747,586 5,197,006 3,859,435 13.23%
NOSH 4,067,978 4,056,733 4,042,481 3,958,563 3,024,522 2,330,496 1,920,116 8.52%
Ratio Analysis
31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/10/13 31/10/12 CAGR
NP Margin 9.23% -7.57% 10.74% 22.21% 23.65% 14.85% 15.34% -
ROE 2.36% -2.72% 2.82% 5.63% 9.57% 8.05% 10.20% -
Per Share
31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/10/13 31/10/12 CAGR
RPS 92.28 79.57 97.19 91.34 132.16 139.93 131.59 -3.79%
EPS 3.75 -11.19 5.27 14.82 26.77 17.95 20.51 -16.90%
DPS 0.65 0.00 1.00 8.55 15.50 11.00 14.00 -28.44%
NAPS 2.96 2.91 3.02 3.03 2.85 2.23 2.01 4.30%
Adjusted Per Share Value based on latest NOSH - 3,958,563
31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/10/13 31/10/12 CAGR
RPS 75.22 64.53 78.54 71.84 90.36 65.19 50.51 4.43%
EPS 5.68 -6.42 6.87 13.41 18.65 8.36 7.87 -3.49%
DPS 0.53 0.00 0.81 6.72 10.60 5.12 5.37 -22.31%
NAPS 2.4128 2.3599 2.4405 2.383 1.9486 1.0389 0.7715 13.23%
Price Multiplier on Financial Quarter End Date
31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/10/13 31/10/12 CAGR
Date 31/12/21 31/12/20 31/12/19 31/12/18 29/12/17 31/10/13 31/10/12 -
Price 1.29 0.99 1.60 2.33 4.00 3.07 3.61 -
P/RPS 1.40 1.24 1.65 2.55 3.03 2.19 2.74 -7.05%
P/EPS 18.50 -12.51 18.82 13.66 14.67 17.10 17.60 0.54%
EY 5.41 -7.99 5.31 7.32 6.82 5.85 5.68 -0.52%
DY 0.50 0.00 0.62 3.67 3.88 3.58 3.88 -20.01%
P/NAPS 0.44 0.34 0.53 0.77 1.40 1.38 1.80 -14.23%
Price Multiplier on Announcement Date
31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/10/13 31/10/12 CAGR
Date 28/02/22 25/02/21 26/02/20 27/02/19 27/02/18 12/12/13 12/12/12 -
Price 1.28 0.915 1.27 2.52 3.29 3.09 3.15 -
P/RPS 1.39 1.15 1.31 2.76 2.49 2.21 2.39 -5.73%
P/EPS 18.35 -11.56 14.94 14.78 12.06 17.21 15.36 1.95%
EY 5.45 -8.65 6.70 6.77 8.29 5.81 6.51 -1.91%
DY 0.51 0.00 0.79 3.39 4.71 3.56 4.44 -21.01%
P/NAPS 0.43 0.31 0.42 0.83 1.15 1.39 1.57 -13.16%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment